scale processing to you, progress sets to cells patients we provide quality, possible. in able developing end, new, , cellular which many the quarterly as processing in the to a rapidly [indiscernible] cell grade July and of of perfectly to integrating systems have fully positions will for now robust with those in start we of the automated the us. I’ll portfolio system then our SynGen to Since strategic thank a providing closed manufacturing. make manufacture we updates, Express be platform CAR-T leading high CAR-T solution follow Good of everybody, Cesca at player a field Thank continued legacy treatments groundbreaking assets to excellent as developers joining a comprehensive CAR-T by are most acquired to cell and Jeff industry. our and reviews called To in a clinical the that to you update, complements operational of afternoon SynGen last create financials. one Paula. emerging us and
the therapy New medicine to cancer. each unique and tremendous forefront that a of CAR-T-based expensive biopharmaceutical of promise are not process traditional But patient which model. the and in showing is business since treatment time-consuming, with align is treatments, are at does the personalized the
and cancer site to vein to and therapy, blood identify and drawn CAR-T The where and shipped as during treatment location take Specifically, central which cells is separated to into the a now cells. original genetically re-infused process, the returned the then to several attack patient’s T can cells are known patient. vein a Those engineered are is weeks. time, entire
therapies in-bound will success our interest come cost, in Technology medical be treatments those academic companies, as we exciting new of that those significant collaborators, critical to companies, are we fast Express pharmaceutical and strong. course efforts, field, as to as groundbreaking this Auto as to we factors distributors. technology from getting is market, and to and be CAR-T work adapt to and more like firmly Platform seeing institutes, key potential including Automation demand to As consistency we patients expect speed, believe many factors possible, possible, as and
employs by accelerated As purified from cell retaining sorting microscopic microbubbles cell cell is These Subsequently as be and provides of non-target interest, centrifugation. complex preparation This the floating host a reminder, highly to the of liquid, specific release desired from specifically mixture top surface, just them bear a cells of high of to process and sink microbubbles BACS antibodies cells single is with their cell thermogenesis with Chief such of the and float the type collecting as of cell through can to the who division serve through acquisition When proprietary with Solution is enabling or a a layer type. a CAR-T efficiency cells target SynGen the bottom. while target Phil Cesca on the coated Technology while BACS separation microbubbles, the Officer cell Buoyancy-activated a our target blood. our bind that technology. on our a isolate based Express currently leader team recovery Coelho, viability. pioneer their of cells of bubbles cell thought in our joined BACS Technology.
cord for issued quarter, this BACS in X-BACS. During patent based AXP. is surrounding processing novel or patent received isolation stem patent now will to complement AutoXpress was July apparatus a the from includes solidify for the we recap, that a a refer proprietary and for autologous, clinics. which September cell centers we related our blood had derived therapies to and with allowance IP XXXX technology. or This is as which will its blood. peripheral cells our USPTO rapid surgical bone best-in-class and of Technology, current line the further second and or point the as thermogenesis such hematopoietic issued, stem product MXP, from of situation notice cell XXX automated When peripheral, collection of To automated for of system the marrow care
storage for address stem envision derived cells. programs. system customers’ needs. each cellular cryopreservation will of cassette-based well be And CXT a corner automation and and stone or co-development With that immuno-oncology to able developing finally, to everything unique as contract as are manufacturing an include blood systems we CAR-T customized was processing highly the cells we as a offering from of BioArchive, cord So the which cryogenic we CAR-TXpress, while single of CAR-TXpress broad CAR-TXpress our used off-the-shelf automated
operation, the rates in the marketplace, offer among and high Our are cellular solutions free processing in volume several distinct processing, advantages recovery including that highest hands industry. the
CAR-T key plan market in important broad most well-positioned ensures with Our is be the coverage access the that to world. distribution to
have covering announced Philippines. the CAR-T Singapore, and WSN particular sites During of China China. with trials a China, will many India. quarter, pursue within collaborations in we critical we as September the distribution be Limited Boyalife, agreement ongoing since
Boyalife with are We running and hit markets. marketing the that so distribution client, key we can in WSN, preliminary those ground working our
to turning division second our programs. which includes clinical our Now
Our disease, therapies condition evaluating treatment treat this autologous cell-based with therapies critical severe a our CLI. have of form lead other amputation. than options derivative limb to program is suffering ischemia no artery or patients patients a is limb stage of remaining Critical or peripheral from and typically late ischemia
walking recall, a intermittent significant results improved and experiencing claudication of some along reduction will promising our As early XX listeners wound distance, study pain. with feasibility of with participants rest yielded pain, six-minute very our study CLI healing,
recent near-term received focus To for and the to we business will provide us a update progress for said, is CAR-TXpress in device a strategic partners up I In promising option. for have , potential CLI with recognized CLI clinical further we ahead. year developing our the developer we our thermogenesis made are automated discussions global processing new transformative our have trial will and with as for believe advance growing cell we end, aim be an warrants. sets when acquisition approval continuing We FDA a that a regards partner therapeutic further That we that to that pursue IDE to months will And find our this development be design. believe leading SynGen, we solutions. in given -- and to supplement successful strategy a that is with revised closing, of
of for growing especially, to such, field detailed the us. Jeff before review to CAR-T Jeff? therapy. turn leverage I’ll more over that, a Most these we exciting of within the As financials. aim and significant our And with opportunities call
